Unknown

Dataset Information

0

Essential Oil of Mentha aquatica var. Kenting Water Mint Suppresses Two-Stage Skin Carcinogenesis Accelerated by BRAF Inhibitor Vemurafenib.


ABSTRACT: The v-raf murine sarcoma viral homolog B1 (BRAF) inhibitor drug vemurafenib (PLX4032) is used to treat melanoma; however, epidemiological evidence reveals that it could cause cutaneous keratoacanthomas and squamous cell carcinoma in cancer patients with the most prevalent HRASQ61L mutation. In a two-stage skin carcinogenesis mouse model, the skin papillomas induced by 7,12-dimethylbenz[a]anthracene (DMBA)/12-O-tetradecanoylphorbol-13-acetate (TPA) (DT) resemble the lesions in BRAF inhibitor-treated patients. In this study, we investigated the bioactivity of Mentha aquatica var. Kenting Water Mint essential oil (KWM-EO) against PDV cells, mouse keratinocytes bearing HRASQ61L mutation, and its effect on inhibiting papilloma formation in a two-stage skin carcinogenesis mouse model with or without PLX4032 co-treatment. Our results revealed that KWM-EO effectively attenuated cell viability, colony formation, and the invasive and migratory abilities of PDV cells. Induction of G2/M cell-cycle arrest and apoptosis in PDV cells was also observed. KWM-EO treatment significantly decreased the formation of cutaneous papilloma further induced by PLX4032 in DT mice (DTP). Immunohistochemistry analyses showed overexpression of keratin14 and COX-2 in DT and DTP skin were profoundly suppressed by KWM-EO treatment. This study demonstrates that KWM-EO has chemopreventive effects against PLX4032-induced cutaneous side-effects in a DMBA/TPA-induced two-stage carcinogenesis model and will be worth further exploration for possible application in melanoma patients.

SUBMITTER: Chang CT 

PROVIDER: S-EPMC6630265 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Essential Oil of <i>Mentha aquatica var. Kenting Water Mint</i> Suppresses Two-Stage Skin Carcinogenesis Accelerated by BRAF Inhibitor Vemurafenib.

Chang Chih-Ting CT   Soo Wen-Ni WN   Chen Yu-Hsin YH   Shyur Lie-Fen LF  

Molecules (Basel, Switzerland) 20190625 12


The v-raf murine sarcoma viral homolog B1 (BRAF) inhibitor drug vemurafenib (PLX4032) is used to treat melanoma; however, epidemiological evidence reveals that it could cause cutaneous keratoacanthomas and squamous cell carcinoma in cancer patients with the most prevalent <i>HRAS</i><sup>Q61L</sup> mutation. In a two-stage skin carcinogenesis mouse model, the skin papillomas induced by 7,12-dimethylbenz[a]anthracene (DMBA)/12-<i>O</i>-tetradecanoylphorbol-13-acetate (TPA) (DT) resemble the lesio  ...[more]

Similar Datasets

| S-EPMC3052309 | biostudies-literature
| S-EPMC5844757 | biostudies-literature
| S-EPMC5333409 | biostudies-literature
| S-EPMC7466659 | biostudies-literature
| S-EPMC3550711 | biostudies-literature
| S-EPMC8912525 | biostudies-literature
| S-EPMC4971773 | biostudies-literature
2016-06-21 | GSE83592 | GEO
| S-EPMC6719046 | biostudies-literature
| S-EPMC3724515 | biostudies-literature